Pharmaceuticals

Hikal Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 79 filings·Updated 13 Oct 2026
Showing 10 of 79 filings.
13 Oct 20262 filings
Company UpdateCopy of Newspaper Publication

Hikal Limited has informed the Exchange about Copy of Newspaper Publication

No brief for this announcement.Newspaper publications aren’t summarised. View the original using the link below
Filed 17:32View Source
Company UpdateNewspaper Publication

Newspaper Publication regarding Special Window for Transfer and Dematerialization of physical securities

No brief for this announcement.Newspaper publications aren’t summarised. View the original using the link below
Filed 17:28View Source
7 Oct 20261 filing
Company UpdateCertificate under SEBI (Depositories and Participants) Regulations, 2018

Hikal Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 11:46View Source
1 Oct 20261 filing
Company UpdateChange in Directorate

Hikal Limited has informed the Exchange about Resignation of Director/KMP/SMP

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 15:21View Source
29 Sept 20261 filing
Company UpdateGeneral

Crisil ESG Rating 65 assigned to Hikal for FY2025-26 based on public data

ESG Rating Update

  • Crisil ESG Rating 65 assigned to Hikal for FY2025-26.
  • Rating prepared independently by Crisil based on public data; no engagement by Hikal.
  • Company highlighted renewables share, waste recycling, and low water withdrawal as strengths.
  • Governance strengths include adequate board strength and high female director representation.
  • Zero whistle-blower and investor complaints reported.
  • Zero safety incidents and zero recalls noted.
  • ESG rating provider categorized under Pharmaceuticals sector per Sept 28, 2026 report.
  • Date of report: September 28, 2026.
Filed 16:15View Source
28 Sept 20261 filing
Insider Trading / SASTClosure of Trading Window

Hikal Limited: Trading Window closed from October 01, 2026 till the expiry of 48 hours from the declaration of financial results for the quarter and half-year ending September 30, 2026

Hikal Limited: Trading Window closed from October 01, 2026 till the expiry of 48 hours from the declaration of financial results for the quarter and half-year ending September 30, 2026

Filed 14:40View Source
22 Sept 20262 filings
Company UpdatePress Release / Media Release

Hikal Begins Commercial Production at Panoli cGMP Facility, Entering Personal Care

Commercialization & Facility

  • New cGMP multipurpose Panoli facility commissioned for personal care production.
  • First production batches completed; samples validated; positive customer feedback.
  • Initial focus on skin care with second-generation UV filters.

Strategic & Portfolio

  • Repurposed Panoli asset to meet growing personal care demand.
  • Portfolio includes second-gen UV filters aligned with evolving regulation.

Sustainability & Recognition

  • EcoVadis Gold Medal: 84/100 score; top 5% globally; 97th percentile.

Operations & Growth Initiatives

  • New cGMP pilot plant at Pune R&T campus enhances process development.
  • Broader strategy to build high-value growth platforms alongside core businesses.
Filed 13:44View Source
Company UpdatePress Release / Media Release

Hikal commences commercial production at Panoli cGMP facility for Personal Care.

Panoli facility begins production

  • Panoli cGMP multipurpose facility begins commercial production.

Product portfolio and approvals

  • Second-generation UV filters in portfolio; global customer approvals in process.

Production milestones and feedback

  • First production batches manufactured; samples validated; positive customer feedback.

R&D and capability expansion

  • Pune R&T campus pilot plant commissioned to strengthen CDMO development.

Sustainability recognition

  • EcoVadis Gold Medal rating 84/100; top 5% globally.

Strategic implications

  • Entry into Personal Care complements Pharma and Crop Protection growth.
Filed 13:38View Source
2 Sept 20261 filing
Company UpdateAnalyst / Investor Meet

Hikal to hold in-person group analyst/institutional meeting in Pune on Sept 4, 2026

Meeting Details

  • Date & time: September 04, 2026, 12:00 P.M. IST onwards.
  • Nature: Group meeting.
  • Mode: In-person.
  • Place: Pune.

Participants

  • Participants: Company officials for investor interactions with analysts/institutional investors.

Purpose

  • Purpose: General investor interaction based on publicly available information.
Filed 10:24View Source
1 Sept 20261 filing
Company UpdateCopy of Newspaper Publication

Hikal Limited has informed the Exchange about Copy of Newspaper Publication

No brief for this announcement.Newspaper publications aren’t summarised. View the original using the link below
Filed 13:53View Source
Showing 10 of 79 filings